Article info
PDFSystemic lupus erythematosus
Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus
- Correspondence to Associate Professor Mandana Nikpour, University of Melbourne, Melbourne, VIC 3065, Australia; m.nikpour{at}unimelb.edu.au
Citation
Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus
Publication history
- Received September 11, 2018
- Revised December 17, 2018
- Accepted January 3, 2019
- First published January 24, 2019.
Online issue publication
April 12, 2019
Article Versions
- Previous version (24 January 2019).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.